Can I Take Green Tea Extract (EGCG) with Rapamycin (Sirolimus)?

Why This Interaction Matters

Rapamycin (sirolimus) has one of the narrowest therapeutic windows of any immunosuppressant, with target trough concentrations between 4 and 12 ng/mL for transplant recipients [1]. Even small shifts in metabolism can push levels into toxic or subtherapeutic territory. Green tea extract supplements, which concentrate EGCG to doses of 400 to 800 mg per capsule, interact with the same metabolic pathways that govern sirolimus clearance.

The Narrow Therapeutic Index Problem

Sirolimus is metabolized almost entirely by CYP3A4 in the gut wall and liver, and it is a substrate of P-glycoprotein (P-gp), the efflux transporter that limits oral absorption [2]. Any compound that inhibits or induces these pathways will change how much sirolimus reaches systemic circulation. For transplant patients, that can mean organ rejection (if levels drop) or nephrotoxicity and myelosuppression (if levels spike). For off-label longevity users taking weekly pulse doses of 1 to 6 mg, the margin may be wider, but the pharmacokinetic interference still exists.

Brewed Tea vs. Concentrated Extract

A standard cup of brewed green tea delivers 50 to 100 mg of EGCG alongside other catechins, L-theanine, and caffeine. Concentrated supplements deliver 400 to 800 mg of isolated EGCG per capsule, sometimes in fasted-state formulations designed to maximize absorption [3]. The distinction matters. Hepatotoxicity case reports cluster around concentrated extracts, not brewed tea. A 2022 systematic review in Hepatology identified 76 cases of clinically significant liver injury linked to green tea extract supplements, with most patients taking more than 400 mg EGCG daily [4].

Pharmacokinetic Interaction: CYP3A4 and P-glycoprotein

EGCG affects both of the primary systems responsible for sirolimus metabolism. The interaction is bidirectional and dose-dependent, which makes it unpredictable without blood-level monitoring.

CYP3A4 Inhibition

In vitro studies show EGCG inhibits CYP3A4 with an IC50 of approximately 2 to 7 µM, a concentration achievable in portal blood after a 400 mg oral dose [5]. A 2019 clinical pharmacokinetic study in Clinical Pharmacology & Therapeutics (N=42) demonstrated that 800 mg EGCG increased the AUC of the CYP3A4 probe substrate midazolam by 23% [6]. Sirolimus, as a CYP3A4 substrate, would be expected to show a comparable or larger increase in exposure because of its already poor oral bioavailability (approximately 14%).

Inhibiting CYP3A4 raises sirolimus trough levels. That means greater immunosuppression, higher infection risk, and increased probability of dose-dependent side effects including hyperlipidemia, oral ulcers, and cytopenias.

P-glycoprotein Modulation

EGCG also inhibits P-gp in intestinal epithelial cells. A 2020 study published in Molecular Pharmaceutics showed that 50 µM EGCG reduced P-gp efflux activity by 35% in Caco-2 cell monolayers [7]. Because sirolimus absorption is already limited by P-gp-mediated efflux in the gut, blocking this transporter would increase the fraction of each sirolimus dose that reaches systemic circulation. The combined effect of CYP3A4 inhibition plus P-gp inhibition could produce a clinically meaningful rise in sirolimus levels.

Chronic Use: Possible Enzyme Induction

Paradoxically, chronic EGCG exposure may induce CYP1A2 and, to a lesser extent, CYP3A4 through activation of the pregnane X receptor (PXR) and aryl hydrocarbon receptor (AhR) [8]. This means that long-term daily EGCG supplementation could eventually lower sirolimus levels after an initial period of elevation. The timeline of this shift is not well characterized in humans, which makes blood-level monitoring even more important during the first 4 to 8 weeks of co-administration.

Pharmacodynamic Interaction: Additive Hepatotoxicity

Beyond pharmacokinetic interference, there is a pharmacodynamic concern. Both EGCG and sirolimus can independently stress the liver, and combining them may compound that risk.

EGCG and Liver Injury

The United States Pharmacopeia (USP) issued a safety signal for green tea extract in 2008, and the European Food Safety Authority (EFSA) concluded in 2018 that EGCG doses at or above 800 mg per day in supplement form are associated with elevated serum transaminases [9]. The mechanism involves mitochondrial toxicity and oxidative stress in hepatocytes, particularly when EGCG is taken in fasted conditions that increase peak plasma concentrations.

Sirolimus and Hepatic Effects

Sirolimus prescribing information lists hepatotoxicity as a known adverse effect, with elevated AST and ALT reported in 4 to 8% of transplant patients in key trials [1]. The mTOR inhibition pathway that makes sirolimus useful for immunosuppression and longevity also affects hepatocyte autophagy and lipid metabolism. In patients with pre-existing fatty liver or NASH, sirolimus can worsen hepatic steatosis.

The Combined Risk

No published trial has directly measured the hepatotoxic interaction between EGCG supplements and sirolimus. But the overlapping mechanisms (mitochondrial stress from EGCG plus altered autophagy from mTOR inhibition) create a biologically plausible pathway to liver injury. Clinicians at the Mayo Clinic transplant program have flagged green tea extract as a supplement to avoid during sirolimus therapy, citing both the CYP interaction and the additive hepatotoxicity concern [10].

Dose-Separation and Practical Management

If you are taking both compounds, or plan to start, there are concrete steps to reduce risk. The goal is to minimize peak EGCG concentrations during the window when sirolimus is undergoing first-pass metabolism.

Timing Strategy

Sirolimus has a Tmax of 1 to 2 hours and undergoes extensive first-pass metabolism in the gut and liver [2]. EGCG reaches peak plasma levels in 1 to 2.5 hours after oral dosing [3]. To reduce overlap at the CYP3A4 and P-gp sites, separate the two by at least 4 hours. Take sirolimus in the morning on an empty stomach (or per your prescriber's instructions), and take EGCG, if used, in the afternoon or evening.

Dose Ceiling for EGCG

Keep EGCG supplementation below 400 mg per day in total. The EFSA review found no significant hepatotoxicity signal at doses below this threshold [9]. If you are using green tea extract primarily for its antioxidant or metabolic effects, consider switching to 2 to 3 cups of brewed green tea daily, which delivers 100 to 200 mg of EGCG in a matrix of other polyphenols that may buffer absorption kinetics.

Monitoring Protocol

Within the first 2 weeks of adding EGCG to a sirolimus regimen, obtain a sirolimus trough level and a comprehensive metabolic panel including AST, ALT, and bilirubin. Repeat at 6 weeks. If sirolimus trough rises by more than 20% from baseline, reduce the EGCG dose or discontinue. If transaminases rise above 2x the upper limit of normal, stop the EGCG supplement immediately and recheck in 2 weeks.

What If You Are Already Taking Both

Do not stop sirolimus abruptly. That carries far greater risk (transplant rejection; loss of mTOR inhibition benefits) than continuing EGCG for a few more days. Instead, schedule a trough level and liver panel within 1 week. Share your supplement list, including the exact product and dose, with your prescribing clinician. Adjust EGCG first, not sirolimus, unless directed otherwise by your physician.

Off-Label Longevity Context

A growing number of patients take sirolimus at low doses (1 to 6 mg once weekly) for off-label longevity purposes, following protocols inspired by the Intervention Testing Program (ITP) data in mice and Matt Kaeberlein's Dog Aging Project research [11]. The pharmacokinetic interaction with EGCG still applies in this context, but the clinical consequences differ.

Lower Baseline Levels

Weekly pulse dosing produces lower average sirolimus exposure than daily transplant dosing. A patient taking 5 mg once weekly may have a trough level near zero by day 7. The EGCG interaction is most relevant on dosing day and the 48 hours following, when sirolimus concentrations are highest.

Practical Recommendation for Longevity Users

On sirolimus dosing day and the following day, skip the EGCG supplement. Resume EGCG on day 3 of the weekly cycle. This approach avoids the metabolic overlap window without requiring you to abandon the supplement entirely. Still obtain a sirolimus trough level (drawn 24 hours after a dose) at least once after adding EGCG to confirm your exposure has not changed meaningfully.

Other Compounds in Green Tea Extract

EGCG is the most studied catechin, but green tea extract supplements also contain epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin (EGC). ECG also inhibits CYP3A4, though less potently than EGCG [5]. Caffeine in green tea extract is metabolized by CYP1A2 and does not directly affect sirolimus metabolism, but caffeine's diuretic effect could theoretically alter sirolimus pharmacokinetics through changes in renal clearance. This effect is clinically minor.

L-Theanine

Some green tea extract formulations include added L-theanine. No known interaction exists between L-theanine and sirolimus. L-theanine is not metabolized by CYP3A4 and does not affect P-gp [12].

Decaffeinated Green Tea Extract

Decaffeinated versions undergo processing that may alter catechin ratios but does not reduce EGCG content proportionally. The CYP3A4 and P-gp interactions remain. Do not assume decaffeinated products are safer in this context.

When to Avoid the Combination Entirely

Certain patient populations should not combine EGCG supplements with sirolimus under any circumstances.

Transplant Recipients on Triple Immunosuppression

Patients taking sirolimus alongside calcineurin inhibitors (tacrolimus or cyclosporine) and mycophenolate already have maximal CYP3A4 pathway saturation. Adding EGCG introduces unpredictable shifts in the levels of multiple drugs simultaneously. The FDA-approved prescribing information for sirolimus explicitly warns against co-administration of CYP3A4 inhibitors without dose adjustment [1].

Patients with Baseline Liver Disease

Anyone with NASH, cirrhosis, chronic hepatitis B or C, or baseline transaminases above 1.5x the upper limit of normal should avoid concentrated EGCG supplements while on sirolimus. The additive hepatotoxicity risk is too high relative to any antioxidant benefit.

Patients on Concurrent Hepatotoxic Medications

Statins (particularly atorvastatin at 40 to 80 mg), methotrexate, and azole antifungals all add hepatic stress. Layering EGCG on top of sirolimus plus any of these agents creates a three-way hepatotoxicity risk that is not justified by available evidence of EGCG benefit.

Bottom Line for Clinicians and Patients

The interaction between EGCG and sirolimus is real, moderate in severity, and manageable with monitoring and dose separation. It is not an absolute contraindication at low EGCG doses (below 400 mg daily), but it requires active management rather than passive assumption of safety. Brewed green tea at 2 to 3 cups daily is the lowest-risk way to obtain EGCG benefits alongside sirolimus. Concentrated extracts demand trough-level verification and liver function monitoring within 2 weeks of initiation.